v520
Vaccineexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2003 (NCT00894114)
Timeline
Indications
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- v520
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00080106 | Phase 2 | Jun 1, 2004 | National Institute of Allergy and Infectious Diseases (NIAID), University of Colorado, Denver |
| NCT00857311 | Phase 1 | May 1, 2004 | Merck |
| NCT00849732 | Phase 1 | Jun 1, 2003 | HIV Vaccine Trials Network, Merck, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00894114 | Phase 1 | May 1, 2003 | Merck |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 3 | 3 | 1 | 2003 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 1 | 2 | 2003 |
| HIV Vaccine Trials Network | Academic/Hospital | 1 | 0 | 1 | 2003 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2004 |
4 organizations
Page 1 / 1